pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$ARVNARVINAS, INC.

$ARVN8.99000.00%
New Haven, CT, USupdated 10h ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
3
marketed
0
phase 3
0
catalysts ytd
3
approvals ytd
0
recalls ytd
0

Pipeline(3)

pipeline depth3 products
Phase 1: 1Phase 2: 1pre_registration: 1
1Phase 11Phase 21pre_registration
Phase 2
ARV-806
Colorectal Cancer
Phase 1
zaloblideg
Diffuse Large B-Cell Lymphoma
pre_registration
vepdegestrant
Human Epidermal Growth Factor Receptor 2 Negative Breast…

📅 Upcoming

Nov 4, 2026
earnings
$ARVN8.99000.00%
in 3mo
ARVINAS, INC. earnings
ARVINAS, INC.
→

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase2A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutationrecruitingn=159
  • phase1A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.recruitingn=255
  • phase2A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgerycompletedn=152
  • phase2Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancercompletedn=248

Insider activity

source: SEC Form 4

open-market buys + sells

  • Mar 18, 26SELLBerkowitz Noah· Chief Medical Officer6,435 sh @ $11.10−$71K↗
  • Mar 6, 26BUYMorrison Briggs· director20,000 sh @ $13.40$268K↗
  • Feb 27, 26SELLHouston John G· director18,822 sh @ $13.24−$249K↗
  • Feb 27, 26SELLHouston John G· director11,787 sh @ $13.14−$155K↗
  • Feb 27, 26SELLHouston John G· director4,688 sh @ $13.24−$62K↗
  • Feb 23, 26SELLTeel Randy· President and CEO3,748 sh @ $12.16−$46K↗
  • Feb 23, 26SELLCacace Angela M· Chief Scientific Officer2,571 sh @ $12.16−$31K↗
  • Feb 23, 26SELLLoomis David K· Chief Accounting Officer1,108 sh @ $12.16−$13K↗
  • Feb 23, 26SELLCacace Angela M· Chief Scientific Officer1,038 sh @ $12.16−$13K↗
  • Feb 23, 26SELLTeel Randy· President and CEO1,038 sh @ $12.16−$13K↗
routine RSU / option mechanics (6)
  • Feb 26, 26grantBerkowitz Noah · Chief Medical Officer67,000 sh
  • Feb 26, 26grantSaik Andrew · Chief Financial Officer45,000 sh
  • Feb 26, 26grantSaik Andrew · Chief Financial Officer67,000 sh
  • Feb 26, 26grantTeel Randy · President and CEO147,791 sh
  • Feb 26, 26grantTeel Randy · President and CEO218,691 sh
  • Feb 26, 26grantLoomis David K · VP, Chief Accounting Officer18,504 sh
🐶 Hiring Signal
next earnings Nov 4, 2026
3 open roles at ARVINAS, INC. →

Where ARVINAS, INC. is staffing up — a leading indicator of pipeline and commercial priorities.

therapeutic areaCNS / Neuroscience 2Oncology 1
departmentR&D / Discovery 2Medical Affairs 1

News

no news has mentioned this company yet
identifiers
ticker
$ARVN
SEC CIK
0001655759
country
US
source
sec_tickers
top tags
Oncology3Colorectal Cancer1DLBCL1NSCLC1
mentioned in
0news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 46m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?